<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740971</url>
  </required_header>
  <id_info>
    <org_study_id>k（2018）43</org_study_id>
    <nct_id>NCT03740971</nct_id>
  </id_info>
  <brief_title>Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke</brief_title>
  <acronym>RICAMIS</acronym>
  <official_title>Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke (RICAMIS): a Prospective, Random, Open Label, Blinded End Point, Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current treatment based on evidence-based medicine for acute ischemic stroke mainly&#xD;
      includes reperfusion (intravenous thrombolysis, mechanical thrombolysis), anti-platelet and&#xD;
      stroke units. About 1/3 patients can obtain good prognosis through intravenous thrombolysis.&#xD;
      Good prognosis can be gotten from about 50 percent of patients with big artery disease by&#xD;
      mechanical embolization. However, only a small proportion of the population can be treated&#xD;
      with restoration perfusion in the time window. The main purpose of antiplatelet therapy is to&#xD;
      prevent the recurrence and progression of stroke, and stroke unit is a kind of management&#xD;
      mode. How to improve the neurological function of patients has been a hot and difficult&#xD;
      problem in clinical practice.&#xD;
&#xD;
      A large number of basic and clinical studies have proved that remote ischemic conditioning&#xD;
      (RIC) has protective effect on ischemic stroke. Hahn et al showed that RIC could play a&#xD;
      neuroprotective role in cerebral ischemia-reperfusion injury in MCAO model. Other studies&#xD;
      have also confirmed that preconditioning RIC has a neuroprotective effect on cerebral&#xD;
      ischemia in animal models. One open label study by Hougaard et al shows that RIC can improve&#xD;
      the NIHSS score in acute ischemic stroke patients. One recent study found that 300&#xD;
      consecutive days RIC therapy for the patients with symptomatic intracranial atherosclerotic&#xD;
      stenosis significantly reduced the recurrence rate of stroke, improved the mRS score and&#xD;
      recovered the blood flow in the lesion site. Furthermore, several studies have also shown&#xD;
      that RIC can not only improve the neurological function of patients with cerebral infarction&#xD;
      after intravenous thrombolysis and mechanical thrombolysis, but also protect the secondary&#xD;
      brain injury after carotid stenting. These results suggest that RIC has a neuroprotective&#xD;
      effect on ischemic stroke and deserves further study.&#xD;
&#xD;
      Based on the above discussion, this study aims to explore the efficacy and safety of RIC in&#xD;
      the treatment of acute moderate ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 26, 2018</start_date>
  <completion_date type="Actual">April 19, 2021</completion_date>
  <primary_completion_date type="Actual">April 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of mRS (0-1）</measure>
    <time_frame>90±7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of mRS (0-2）</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of early neurological deterioration</measure>
    <time_frame>7 days</time_frame>
    <description>more than 4 NIHSS score increase compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stroke associated pneumonia</measure>
    <time_frame>12±2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of stroke or other vascular events</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of death of any cause</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1800</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Guideline-based therapy+RIC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RIC is given twice a day with 200mmHg pressure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Guideline-based therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Remote Ischemic Conditioning treatment</intervention_name>
    <description>Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.</description>
    <arm_group_label>Guideline-based therapy+RIC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guideline-based therapy</intervention_name>
    <description>Guideline-based therapy</description>
    <arm_group_label>Guideline-based therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient age ≥18 years;&#xD;
&#xD;
          2. From onset to treatment ≤ 48 hours;&#xD;
&#xD;
          3. Ischemic stroke confirmed by head CT or MRI;&#xD;
&#xD;
          4. 6≤NIHSS score ≤ 16;&#xD;
&#xD;
          5. Premorbid mRS ≤ 1;&#xD;
&#xD;
          6. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious neurological deficits before onset ( mRS ≥ 2)；&#xD;
&#xD;
          2. The aetiology of cardiogenic embolism, such as rheumatic mitral or aortic stenosis,&#xD;
             artificial heart valve, atrial fibrillation, atrial flutter, sick sinus syndrome, left&#xD;
             atrial myxoma, left ventricular wall thrombus or valve neoplasm, congestive heart&#xD;
             failure, bacterial endocarditis, etc;&#xD;
&#xD;
          3. Uncontrolled severe hypertension (Systolic pressure ≥180 mmHg or diastolic pressure&#xD;
             ≥110 mmHg after drug treatment);&#xD;
&#xD;
          4. Subclavian artery stenosis ≥ 50% or subclavian steal syndrome;&#xD;
&#xD;
          5. Intracranial tumor, arteriovenous malformation or aneurysm;&#xD;
&#xD;
          6. Severe abnormalities in coagulation;&#xD;
&#xD;
          7. Any contraindication for remote ischemic adaptation: the upper limb has serious soft&#xD;
             tissue injury, fracture or vascular injury, distal upper limb perivascular lesions,&#xD;
             etc.;&#xD;
&#xD;
          8. Comorbidity with any serious diseases and life expectancy is less than half a year;&#xD;
&#xD;
          9. Participating in other clinical trials within 3 months;&#xD;
&#xD;
         10. Patients not suitable for this clinical studies considered by researcher;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huisheng Chen, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Neurology Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital of ShenYang Military Region</name>
      <address>
        <city>ShenYang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Department director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

